EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Swedish Orphan Biovitrum AB's Enterprise Value is €9,509 Mil.
Swedish Orphan Biovitrum AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €342 Mil. Therefore, Swedish Orphan Biovitrum AB's EV-to-EBIT for today is 27.82.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's EV-to-EBIT or its related term are showing as below:
FRA:B6E'
s EV-to-EBIT Range Over the Past 10 Years
Min: -363.53 Med: 19.71 Max: 262.87
Current: 27.33
During the past 13 years, the highest EV-to-EBIT of Swedish Orphan Biovitrum AB was 262.87. The lowest was -363.53. And the median was 19.71.
FRA:B6E's EV-to-EBIT is ranked worse than 70.15% of 670
companies
in the Drug Manufacturers industry
Industry Median: 17.115
vs FRA:B6E: 27.33
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Swedish Orphan Biovitrum AB's Enterprise Value for the quarter that ended in Mar. 2024 was €0 Mil.
Swedish Orphan Biovitrum AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €342 Mil. Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.
Swedish Orphan Biovitrum AB EV-to-EBIT Historical Data
The historical data trend for Swedish Orphan Biovitrum AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Swedish Orphan Biovitrum AB's EV-to-EBIT
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's EV-to-EBIT falls into.
Swedish Orphan Biovitrum AB EV-to-EBIT Calculation
Swedish Orphan Biovitrum AB's EV-to-EBIT for today is calculated as:
Swedish Orphan Biovitrum AB's current Enterprise Value is €9,509 Mil.
Swedish Orphan Biovitrum AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €342 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (FRA:B6E) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Swedish Orphan Biovitrum AB's Enterprise Value for the quarter that ended in Mar. 2024 was €0 Mil.
Swedish Orphan Biovitrum AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €342 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum AB (FRA:B6E) Business Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:B6E has been successfully added to your 